JP2004231600A - Skin care preparation for external use - Google Patents
Skin care preparation for external use Download PDFInfo
- Publication number
- JP2004231600A JP2004231600A JP2003024614A JP2003024614A JP2004231600A JP 2004231600 A JP2004231600 A JP 2004231600A JP 2003024614 A JP2003024614 A JP 2003024614A JP 2003024614 A JP2003024614 A JP 2003024614A JP 2004231600 A JP2004231600 A JP 2004231600A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- external preparation
- derivative
- sesquioxide
- germanium sesquioxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 229940093626 germanium sesquioxide Drugs 0.000 claims abstract description 31
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 13
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
- 210000003491 skin Anatomy 0.000 claims description 35
- IQULGZQMMPRBLA-UHFFFAOYSA-N 2-carboxyethylgermanium Chemical compound OC(=O)CC[Ge] IQULGZQMMPRBLA-UHFFFAOYSA-N 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 10
- 239000003623 enhancer Substances 0.000 claims description 10
- -1 fatty acid ester Chemical class 0.000 claims description 10
- 210000004927 skin cell Anatomy 0.000 claims description 7
- 230000036560 skin regeneration Effects 0.000 claims description 7
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 claims description 3
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- CWLQUGTUXBXTLF-UHFFFAOYSA-N N-methyl-L-proline monohydrate Natural products CN1CCCC1C(O)=O CWLQUGTUXBXTLF-UHFFFAOYSA-N 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 239000006096 absorbing agent Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims description 2
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical group OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229940051250 hexylene glycol Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229960000448 lactic acid Drugs 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- FOWDZVNRQHPXDO-UHFFFAOYSA-N propyl hydrogen carbonate Chemical compound CCCOC(O)=O FOWDZVNRQHPXDO-UHFFFAOYSA-N 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 229940071139 pyrrolidone carboxylate Drugs 0.000 claims description 2
- 239000003352 sequestering agent Substances 0.000 claims description 2
- 239000001540 sodium lactate Substances 0.000 claims description 2
- 229940005581 sodium lactate Drugs 0.000 claims description 2
- 235000011088 sodium lactate Nutrition 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 229940045136 urea Drugs 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 15
- 230000003110 anti-inflammatory effect Effects 0.000 description 11
- 230000002745 absorbent Effects 0.000 description 9
- 239000002250 absorbent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000006071 cream Substances 0.000 description 7
- 238000010998 test method Methods 0.000 description 6
- 239000006210 lotion Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【０００１】
【発明の属する技術分野】
本発明は、皮膚外用剤に関し、より詳しくは、保湿剤、消炎剤、皮膚再生剤、皮膚細胞活性化剤等の皮膚炎治癒剤として適用可能な皮膚外用剤に関する。
【０００２】
【従来の技術】
従来、金属酸化物や有機金属化合物等を皮膚外用剤に添加して、種々の効果を得る試みがなされており、例えば、Ｌ−アスコルビン酸複合金属塩を含有させることにより、美白効果を奏する皮膚外用組成物が得られることが報告されている（特許文献１参照）。そして、特許文献１によれば、ゲルマニウムも複合金属塩を合成するために用いることができるとされている。
【０００３】
一方で、保湿性を有する種々の化合物を組み合わせることにより、保湿や消炎等の効果を奏する皮膚外用剤が開発されている。
【０００４】
【特許文献１】
特開２００２−２６５３４８号公報
【０００５】
【発明が解決しようとする課題】
しかしながら、特許文献１に開示されている組成やその他公知の組成を有する皮膚外用剤においては、保湿性の点で更に改良の余地があった。
【０００６】
本発明は、かかる問題点に鑑みてなされたものであり、優れた保湿効果を発揮する皮膚外用剤を提供することを目的とする。
【０００７】
【課題を解決するための手段】
上記目的を達成するために、本発明は、下記一般式（１）で表されるゲルマニウムセスキオキシド誘導体と経皮吸収促進剤とを含有することを特徴とする皮膚外用剤を提供する。なお、式中、Ｒ１は、水素原子がフェニル基で置換されていてもよい炭素数１〜４のアルキレン基（フェニル基で置換される場合、置換の対象であるアルキレン基の炭素数が１〜４であることを意味する。）を示す。
Ｏ３（Ｇｅ−Ｒ１−ＣＯＯＨ）２ …（１）
【０００８】
上記ゲルマニウムセスキオキシド誘導体は、（２−カルボキシエチルゲルマニウム）セスキオキシドが特に好ましい。
【０００９】
また、ゲルマニウムセスキオキシド誘導体の含有量は、皮膚外用剤を基準として０．００１〜５重量％とすることが好適であり、ゲルマニウムセスキオキシド誘導体１００重量部に対する前記経皮吸収促進剤の量は１０〜２０００重量部とすることが好ましい。
【００１０】
本発明に係る皮膚外用剤には、所定の化学構造を有するゲルマニウムセスキオキシド誘導体と経皮吸収促進剤とを組み合わせて含有させていることから、非常に優れた保湿効果を発揮する。また、かかる効果のみならず、保湿、消炎、皮膚再生、皮膚細胞活性化等の各種皮膚炎治癒効果を奏する。
【００１１】
すなわち、上記皮膚外用剤は、保湿用（保湿剤）のみならず、消炎用（消炎剤）、皮膚再生用（皮膚再生剤）又皮膚細胞活性化用（皮膚細胞活性化剤）として用いることができる。
【００１２】
【発明の実施の形態】
本発明に用いられるゲルマニウムセスキオキシド誘導体は、以下の一般式（１）：
Ｏ３（Ｇｅ−Ｒ１−ＣＯＯＨ）２ …（１）
で表されるものであり、Ｒ１は、水素原子がフェニル基で置換されていてもよい炭素数１〜４のアルキレン基を示すが、Ｒ１として好適なものは、−ＣＨ２−ＣＨ２−、−ＣＨ（ＣＨ３）−ＣＨ２−、−ＣＨ２−ＣＨ（ＣＨ３）−、−Ｃ（ＣＨ３）２−ＣＨ２−、−ＣＨ（Ｃ６Ｈ５）−ＣＨ２−、−ＣＨ（Ｃ６Ｈ５）−ＣＨ（ＣＨ３）−であり、−ＣＨ２−ＣＨ２−が特に好適である。したがって、ゲルマニウムセスキオキシド誘導体としては、（２−カルボキシエチルゲルマニウム）セスキオキシドが特に好ましい。
【００１３】
ゲルマニウムセスキオキシド誘導体の配合量は、皮膚外用剤全量中の０．００１〜５重量％であることが好ましく、更に好ましくは０．０５〜２重量％である。０．００１重量％未満では保湿、消炎、皮膚再生、皮膚細胞活性化、及び種々の皮膚炎治癒の相乗効果が充分に発揮されない場合がある。
【００１４】
経皮吸収促進剤としては、ジプロピレングリコール、ヘキシレングリコール、イソパラフィン、ラウリル硫酸ナトリウム、ラウリルアルコールのエチレンオキサイド付加物（エチレンオキサイドモル数：５〜３０）、ポリエチレングリコール脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エステル、炭酸プロピル、ピロリドンカルボン酸ナトリウム、尿素、乳酸、乳酸ナトリウム、レシチン、ジメチルスルフォキサイド、ピロリドンカルボン酸エステル、ニコチン酸エステル、Ｎ−メチルプロリンエステル、オレイン酸コレステリルエステル、アミンオキサイド等が挙げられ、これらを単独もしくは種々の組み合わせで配合できる。経皮吸収促進剤の配合量は種類によって異なるが、皮膚外用剤全量中の０．０１〜１０重量％が好ましく、より好ましくは０．１〜５重量％である。
【００１５】
また、ゲルマニウムセスキオキシド誘導体１００重量部に対する経皮吸収促進剤の量は、１０〜２０００重量部が好ましく、５０〜１０００重量部がより好ましい。
【００１６】
皮膚外用剤には、上記の構成成分に加えて、必要に応じて、通常医薬品、化粧品等皮膚外用剤に用いられるその他の添加成分、例えば、クエン酸ナトリウム、メタリン酸ナトリウム、エデト酸二、三又は四ナトリウム等の金属イオン封鎖剤、酸化防止剤、界面活性剤、紫外線吸収剤、香料、水、エタノールやイソプロパノ‐ル等の低級アルコール、増粘剤、色剤、粉末、薬剤、クエン酸、リンゴ酸等の有機酸、リン酸等の無機酸、アミノ酸、ペプチド、タンパク質、単糖、オリゴ糖、多糖等を配合することができる。なお、上記添加成分の添加量は、本発明の皮膚外用剤が奏する上述した効果を損なわない範囲とする。
【００１７】
皮膚外用剤の剤型は任意であり、溶液系、可溶化系、乳化系、粉末分散系、水−二層系、水−油−粉末三層系等、どのような剤型を採用してもよい。また、皮膚外用剤の用途も任意であり、化粧水、乳液、クリーム、パック剤のフェイシャル、ボディ用皮膚外用剤や軟膏等の外用剤に用いることができる。
【００１８】
更には、化粧水や乳液等を不織布や紙等の支持体に含浸させたウェットタイプのシート状外用剤、あるいは水溶性や油性ゲルのようなパップ外用剤に用いることができる。
【００１９】
【実施例】
以下、本発明の好適な実施例についてさらに詳細に説明するが、本発明はこれらの実施例に限定されるものではない。
【００２０】
［実施例１〜３及び比較例１］
表１に示す、ゲルマニウムセスキオキシド誘導体（（２−カルボキシエチルゲルマニウム）セスキオキシド）及び経皮吸収剤並びにその他添加成分を配合して（表中の数字は重量％）、実施例１〜３及び比較例１の化粧水を作製した。そして、実施例１〜３及び比較例１の化粧水について、実使用テストを実施して、保湿効果を評価した。試験方法は、次のとおりであった。
【００２１】
（試験方法）
２０〜５５歳の男性５名及び女性５名、計１０名を被験者として、前腕内側部にマーカーした４ヶ所の部位に実施例１〜３及び比較例１の化粧水のそれぞれを３０日間、毎日塗布した。塗布前及び３０日間連続塗布した後の各部位の保湿性について、電導度計（アイ・ビイ・エス株式会社製、商品名：スキコン）を用いて表皮の電導度を測定することにより評価した。なお、この電導度は表皮中の水分量を反映した値である。
【００２２】
電導度の測定結果を表２に示す。表２に示すように、ゲルマニウムセスキオキシド誘導体が配合されていない比較例１に比べて、ゲルマニウムセスキオキシド誘導体が配合されている実施例１〜３は電導度が増加した。なお、ゲルマニウムセスキオキシド誘導体の配合量が増加するにつれて電導度の値が増加する傾向にあった。この結果より、ゲルマニウムセスキオキシド誘導体と経皮吸収剤とを併用することにより、保湿性について相乗的な効果が発揮されることがわかった。
【００２３】
【表１】
【表２】
［実施例４〜６及び比較例２］
表３に示す、ゲルマニウムセスキオキシド誘導体（（２−カルボキシエチルゲルマニウム）セスキオキシド）及び経皮吸収剤並びにその他添加成分を配合して（表中の数字は重量％）、実施例４〜６及び比較例２のクリームを作製した。そして、実施例４〜６及び比較例２のクリームについて、実使用テストを実施して、消炎効果を評価した。試験方法は、次のとおりであった。
【００２６】
（試験方法）
２０〜５５歳の男性５名及び女性５名、計１０名４群を被験者として、夏の海辺で３時間、海水浴をした後、それぞれの群に実施例４〜６及び比較例２のクリームのいずれかを適宜３日間にわたって使用してもらい、消炎効果の実感について聞き取り調査を実施した。
【００２７】
その結果を表４に示す。表４の数字は１０名中の満足した（消炎効果があった）と回答した人数である。表４に示すように、ゲルマニウムセスキオキシド誘導体の配合されていない比較例２に比べて、ゲルマニウムセスキオキシド誘導体の配合されている実施例４〜６は優れた消炎効果を発揮した。なお、ゲルマニウムセスキオキシド誘導体の配合量が増加するにつれて消炎効果を増大する傾向にあった。以上より、ゲルマニウムセスキオキシド誘導体と経皮吸収剤とを併用することにより、消炎効果について相乗的な効果が発揮されることがわかった。
【００２８】
【表３】
【表４】
［実施例７〜９及び比較例３］
表５に示す、ゲルマニウムセスキオキシド誘導体（（２−カルボキシエチルゲルマニウム）セスキオキシド）及び経皮吸収剤並びにその他添加成分を配合して（表中の数字は重量％）、実施例７〜９及び比較例３のクリームを作製した。そして、実施例７〜９及び比較例３のクリームについて、実使用テストを実施して、皮膚再生効果を評価した。試験方法は、次のとおりであった。
【００３１】
（試験方法）
２０〜５５歳の男性５名及び女性５名、計１０名を被験者として、背中にマーカーした４ヶ所の部位を予め０．２％ラウリル硫酸ナトリウム水溶液含浸コットンを３時間貼付した後、コットンを取り除き、イオン交換水を含浸させたコットンで洗浄した。その後、実施例７〜９及び比較例３のクリームをそれぞれ１４日間、毎日塗布した。塗布前及び１４日間連続塗布した後の各部位の皮膚再生効果について、ＴＥＷＡメーター（ＣＯＵＲＡＧＥ＋ＫＨＡＺＡＫＡ Ｅｌｅｃｔｒｏｎｉｃ ＧｍｂＨ社製）を用いて経皮水分蒸散量を測定することにより評価した。
【００３２】
結果を表６に示す。表６に示すように、ゲルマニウムセスキオキシド誘導体の配合されていない比較例３に比べて、ゲルマニウムセスキオキシド誘導体の配合されている実施例７〜９はＴＥＷＡ値（ｇ／ｈ・ｍ２）が小さかった。なお、ゲルマニウムセスキオキシド誘導体の配合量が増加するにつれてＴＥＷＡ値が減少する傾向にあった。この結果より、ゲルマニウムセスキオキシド誘導体と経皮吸収剤とを併用することにより、皮膚再生効果について相乗的な効果が発揮されることわかった。
【００３３】
【表５】
【表６】
［表皮角化細胞の増殖促進効果］
ヒト由来の表皮角化細胞に対する（２−カルボキシエチルゲルマニウム）セスキオキシド（ゲルマニウムセスキオキシド誘導体）の増殖促進効果について、ｉｎｖｉｔｒｏで調べた。すなわち、２４ｗｅｌｌの培養プレートに培地としてＦ−１２培地（ヒドロコルチゾン・アデニン・ウシ胎児血清を添加）を用い、表皮角化細胞数を２．５×１０６／ｍＬとして、表７に示す添加剤を添加して、３０℃、５．０％ＣＯ２の条件下で７日間培養した。この場合において、（２−カルボキシエチルゲルマニウム）セスキオキシドの最終濃度は０．０１〜０．４％、経皮吸収促進剤であるイソパラフィン濃度は２．５％、ピロリドンカルボン酸ナトリウム濃度は１．０％とした。
【００３６】
培養後、ＭＴＴアッセイ法により生細胞数をＭＴＴ（３−［４，５−ｄｉｍｅｔｈｙｌｅｔｈｉａｚｏｌ−２−ｙｌ］−２，５−ｄｉｐｈｅｎｙｌｔｅｔｒａｚｏｌｉｕｍｂｒｏｍｉｄｅ）の色調変化（Ｏｐｉｔｉｃａｌ Ｄｅｎｓｉｔｙ（ＯＤと略す）：５７０ｎｍ−６５０ｎｍ）から測定した。
【００３７】
得られた結果を表７に示す。なお、（２−カルボキシエチルゲルマニウム）セスキオキシド及び経皮吸収剤の無添加区のＯＤ値を１００％として計算した。（２−カルボキシエチルゲルマニウム）セスキオキシド及び経皮吸収剤の両方が添加された培地において、（２−カルボキシエチルゲルマニウム）セスキオキシド濃度が０．０５％以上で表皮角化細胞の増殖促進効果が認められた。この結果より、ゲルマニウムセスキオキシド誘導体と経皮吸収剤とを併用することにより、増殖促進効果について相乗的な効果が発揮されることがわかった。
【００３８】
【表７】
【発明の効果】
以上説明したように、本発明によれば、非常に優れた保湿効果を発揮し、更に、保湿、消炎、皮膚再生、皮膚細胞活性化等の各種皮膚炎治癒効果をも発揮する皮膚外用剤が得られる。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a skin external preparation, and more particularly, to a skin external preparation applicable as a dermatitis healing agent such as a humectant, an anti-inflammatory agent, a skin regenerating agent, and a skin cell activator.
[0002]
[Prior art]
Conventionally, attempts have been made to obtain various effects by adding a metal oxide, an organometallic compound, or the like to an external preparation for the skin. For example, by adding an L-ascorbic acid complex metal salt, a skin exhibiting a whitening effect is obtained. It is reported that an external composition can be obtained (see Patent Document 1). According to Patent Document 1, germanium can also be used for synthesizing a composite metal salt.
[0003]
On the other hand, an external preparation for skin which has effects such as moisturizing and anti-inflammation by combining various compounds having moisturizing properties has been developed.
[0004]
[Patent Document 1]
JP, 2002-265348, A
[Problems to be solved by the invention]
However, skin external preparations having the composition disclosed in Patent Document 1 and other known compositions have room for further improvement in terms of moisture retention.
[0006]
The present invention has been made in view of such a problem, and an object of the present invention is to provide a skin external preparation that exhibits an excellent moisturizing effect.
[0007]
[Means for Solving the Problems]
In order to achieve the above object, the present invention provides a skin external preparation characterized by comprising a germanium sesquioxide derivative represented by the following general formula (1) and a transdermal absorption enhancer. In the formula, R 1 is an alkylene group having 1 to 4 carbon atoms, in which a hydrogen atom may be substituted with a phenyl group (when substituted with a phenyl group, the alkylene group to be substituted has 1 carbon atom. ~ 4).
O 3 (Ge-R 1 -COOH) 2 (1)
[0008]
The germanium sesquioxide derivative is particularly preferably (2-carboxyethylgermanium) sesquioxide.
[0009]
The content of the germanium sesquioxide derivative is preferably 0.001 to 5% by weight based on the external preparation for skin, and the amount of the percutaneous absorption enhancer per 100 parts by weight of the germanium sesquioxide derivative is 10% by weight. It is preferably set to ２０００2000 parts by weight.
[0010]
Since the skin external preparation according to the present invention contains a combination of a germanium sesquioxide derivative having a predetermined chemical structure and a transdermal absorption enhancer, it exhibits a very excellent moisturizing effect. In addition to these effects, various dermatitis healing effects such as moisturizing, anti-inflammatory, skin regeneration, and skin cell activation are exhibited.
[0011]
That is, the above-mentioned skin external preparation may be used not only for moisturizing (humectant), but also for anti-inflammatory (anti-inflammatory), skin regenerating (skin regenerating agent) and skin cell activating (skin cell activating agent). it can.
[0012]
BEST MODE FOR CARRYING OUT THE INVENTION
The germanium sesquioxide derivative used in the present invention has the following general formula (1):
O 3 (Ge-R 1 -COOH) 2 (1)
Wherein R 1 represents an alkylene group having 1 to 4 carbon atoms, in which a hydrogen atom may be substituted by a phenyl group, and preferred as R 1 is —CH 2 —CH 2 -, - CH (CH 3) -CH 2 -, - CH 2 -CH (CH 3) -, - C (CH 3) 2 -CH 2 -, - CH (C 6 H 5) -CH 2 -, - CH (C 6 H 5 ) —CH (CH 3 ) —, with —CH 2 —CH 2 — being particularly preferred. Therefore, (2-carboxyethylgermanium) sesquioxide is particularly preferred as the germanium sesquioxide derivative.
[0013]
The compounding amount of the germanium sesquioxide derivative is preferably 0.001 to 5% by weight, more preferably 0.05 to 2% by weight, based on the total amount of the external preparation for skin. If it is less than 0.001% by weight, the synergistic effects of moisturizing, anti-inflammatory, skin regeneration, skin cell activation, and various dermatitis healing may not be sufficiently exhibited.
[0014]
Examples of the transdermal absorption enhancer include dipropylene glycol, hexylene glycol, isoparaffin, sodium lauryl sulfate, ethylene oxide adduct of lauryl alcohol (ethylene oxide mole number: 5 to 30), polyethylene glycol fatty acid ester, polyoxyethylene sorbitan fatty acid Esters, propyl carbonate, sodium pyrrolidone carboxylate, urea, lactic acid, sodium lactate, lecithin, dimethyl sulfoxide, pyrrolidone carboxylate, nicotinate, N-methylproline ester, cholesteryl oleate, amine oxide and the like. These can be blended alone or in various combinations. The amount of the transdermal absorption enhancer varies depending on the kind, but is preferably 0.01 to 10% by weight, more preferably 0.1 to 5% by weight, based on the total amount of the external preparation for skin.
[0015]
Further, the amount of the transdermal absorption enhancer per 100 parts by weight of the germanium sesquioxide derivative is preferably from 10 to 2,000 parts by weight, and more preferably from 50 to 1,000 parts by weight.
[0016]
In the skin external preparation, in addition to the above-mentioned constituent components, if necessary, other additional components usually used in skin external preparations such as pharmaceuticals and cosmetics, for example, sodium citrate, sodium metaphosphate, edetate, Or sequestering agents such as tetrasodium, antioxidants, surfactants, ultraviolet absorbers, fragrances, water, lower alcohols such as ethanol and isopropanol, thickeners, coloring agents, powders, drugs, citric acid, Organic acids such as malic acid, inorganic acids such as phosphoric acid, amino acids, peptides, proteins, monosaccharides, oligosaccharides, polysaccharides and the like can be blended. In addition, the addition amount of the above-mentioned additional component is set to a range that does not impair the above-mentioned effects of the external preparation for skin of the present invention.
[0017]
The dosage form of the external preparation for skin is arbitrary, and any dosage form such as solution type, solubilizing type, emulsifying type, powder dispersing type, water-two-layer type, water-oil-powder three-layer type, etc. is adopted. Is also good. The use of the external preparation for skin is also optional, and it can be used for facial lotions, emulsions, creams, packs, external preparations for body skin and ointments.
[0018]
Furthermore, it can be used as a wet type sheet-shaped external preparation in which a support such as a nonwoven fabric or paper is impregnated with a lotion, an emulsion or the like, or a cataplasmic external preparation such as a water-soluble or oil-based gel.
[0019]
【Example】
Hereinafter, preferred embodiments of the present invention will be described in more detail, but the present invention is not limited to these embodiments.
[0020]
[Examples 1 to 3 and Comparative Example 1]
A germanium sesquioxide derivative ((2-carboxyethylgermanium) sesquioxide), a percutaneous absorbent and other additional components shown in Table 1 were blended (the numbers in the table are% by weight), and Examples 1-3 and Comparative Examples The lotion of Example 1 was prepared. Then, the lotions of Examples 1 to 3 and Comparative Example 1 were subjected to actual use tests to evaluate the moisturizing effect. The test method was as follows.
[0021]
(Test method)
Five males and five females aged 20 to 55 years old, a total of 10 subjects, were treated with the lotions of Examples 1 to 3 and Comparative Example 1 daily at the four sites marked on the inner part of the forearm for 30 days. Applied. The moisturizing property of each part before application and after continuous application for 30 days was evaluated by measuring the electric conductivity of the epidermis using an electric conductivity meter (manufactured by IBS Co., Ltd., trade name: Sukikon). The electric conductivity is a value reflecting the amount of moisture in the skin.
[0022]
Table 2 shows the measurement results of the conductivity. As shown in Table 2, as compared with Comparative Example 1 in which the germanium sesquioxide derivative was not blended, Examples 1 to 3 in which the germanium sesquioxide derivative was blended increased the conductivity. The value of the electrical conductivity tended to increase as the amount of the germanium sesquioxide derivative increased. From these results, it was found that a synergistic effect on moisture retention was exhibited by using the germanium sesquioxide derivative and the transdermal absorbent in combination.
[0023]
[Table 1]
[Table 2]
[Examples 4 to 6 and Comparative Example 2]
A germanium sesquioxide derivative ((2-carboxyethylgermanium) sesquioxide), a percutaneous absorbent and other additional components shown in Table 3 were blended (the numbers in the table are% by weight), and Examples 4 to 6 and Comparative Examples The cream of Example 2 was made. The creams of Examples 4 to 6 and Comparative Example 2 were subjected to actual use tests to evaluate the anti-inflammatory effect. The test method was as follows.
[0026]
(Test method)
A group of 10 males and 5 females aged 20 to 55 years old, a total of 10 subjects, was bathed for 3 hours at the summer seaside for 3 hours, and the creams of Examples 4 to 6 and Comparative Example 2 were added to each group. Either of them was used for 3 days as appropriate, and a hearing survey was conducted on the actual feeling of the anti-inflammatory effect.
[0027]
Table 4 shows the results. The numbers in Table 4 are the number of respondents out of 10 who were satisfied (had an anti-inflammatory effect). As shown in Table 4, as compared with Comparative Example 2 in which the germanium sesquioxide derivative was not blended, Examples 4 to 6 in which the germanium sesquioxide derivative was blended exhibited an excellent anti-inflammatory effect. In addition, the anti-inflammatory effect tended to increase as the amount of the germanium sesquioxide derivative increased. From the above, it was found that the combined use of the germanium sesquioxide derivative and the transdermal absorbent exerts a synergistic effect on the anti-inflammatory effect.
[0028]
[Table 3]
[Table 4]
[Examples 7 to 9 and Comparative Example 3]
A germanium sesquioxide derivative ((2-carboxyethylgermanium) sesquioxide), a transdermal absorbent and other additional components shown in Table 5 were blended (the numbers in the table are% by weight), and Examples 7 to 9 and Comparative Examples The cream of Example 3 was made. The creams of Examples 7 to 9 and Comparative Example 3 were subjected to actual use tests to evaluate the skin regeneration effect. The test method was as follows.
[0031]
(Test method)
Using 10 males and 5 females aged 20 to 55 years old as subjects, the four sites marked on the back were previously affixed with 0.2% sodium lauryl sulfate aqueous solution impregnated cotton for 3 hours, and the cotton was removed. And washed with cotton impregnated with ion-exchanged water. Thereafter, the creams of Examples 7 to 9 and Comparative Example 3 were applied daily for 14 days, respectively. The skin regeneration effect of each site before and after continuous application for 14 days was evaluated by measuring the transepidermal water loss using a TEWA meter (COURAGE + KHAZAKA Electronic GmbH).
[0032]
Table 6 shows the results. As shown in Table 6, the TEWA value (g / h · m 2 ) of Examples 7 to 9 in which the germanium sesquioxide derivative was blended was smaller than that of Comparative Example 3 in which the germanium sesquioxide derivative was not blended. Was. The TEWA value tended to decrease as the amount of the germanium sesquioxide derivative increased. From these results, it was found that the combined use of the germanium sesquioxide derivative and the transdermal absorbent exerts a synergistic effect on the skin regeneration effect.
[0033]
[Table 5]
[Table 6]
[Effect of promoting keratinocyte proliferation]
The growth promoting effect of (2-carboxyethylgermanium) sesquioxide (germanium sesquioxide derivative) on human-derived epidermal keratinocytes was examined in vitro. That is, an F-12 medium (hydrocortisone / adenine / fetal bovine serum was added) was used as a medium in a 24-well culture plate, and the number of epidermal keratinocytes was set to 2.5 × 10 6 / mL, and the additives shown in Table 7 were added. The cells were added and cultured for 7 days at 30 ° C. and 5.0% CO 2 . In this case, the final concentration of (2-carboxyethylgermanium) sesquioxide is 0.01 to 0.4%, the concentration of isoparaffin which is a transdermal absorption enhancer is 2.5%, and the concentration of sodium pyrrolidonecarboxylate is 1.0%. %.
[0036]
After the culture, the number of viable cells was determined by MTT assay from the change in color tone (Optical Density (abbreviated as OD): 570 nm to 650 nm) of MTT (3- [4,5-dimethylethylazol-2-yl] -2,5-diphenyltetrazolium bromide). It was measured.
[0037]
Table 7 shows the obtained results. In addition, the OD value of the non-added section of (2-carboxyethylgermanium) sesquioxide and the transdermal absorbent was calculated as 100%. In a medium to which both (2-carboxyethylgermanium) sesquioxide and a percutaneous absorbent were added, a proliferation promoting effect of epidermal keratinocytes was observed at a (2-carboxyethylgermanium) sesquioxide concentration of 0.05% or more. Was done. From these results, it was found that the combined use of the germanium sesquioxide derivative and the transdermal absorbent exerts a synergistic effect on the growth promoting effect.
[0038]
[Table 7]
【The invention's effect】
As described above, according to the present invention, a skin external preparation that exhibits a very excellent moisturizing effect and further exhibits various dermatitis healing effects such as moisturizing, anti-inflammatory, skin regeneration, and skin cell activation. can get.
Claims (10)
Ｏ３（Ｇｅ−Ｒ１−ＣＯＯＨ）２ …（１）
［式中、Ｒ１は、水素原子がフェニル基で置換されていてもよい炭素数１〜４のアルキレン基を示す。］An external preparation for skin, comprising a germanium sesquioxide derivative represented by the following general formula (1) and a transdermal absorption enhancer.
O 3 (Ge-R 1 -COOH) 2 (1)
[In the formula, R 1 represents an alkylene group having 1 to 4 carbon atoms, in which a hydrogen atom may be substituted by a phenyl group. ]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003024614A JP2004231600A (en) | 2003-01-31 | 2003-01-31 | Skin care preparation for external use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003024614A JP2004231600A (en) | 2003-01-31 | 2003-01-31 | Skin care preparation for external use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004231600A true JP2004231600A (en) | 2004-08-19 |
Family
ID=32953100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003024614A Pending JP2004231600A (en) | 2003-01-31 | 2003-01-31 | Skin care preparation for external use |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2004231600A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1852130A4 (en) * | 2005-02-25 | 2008-04-16 | Hisamitsu Pharmaceutical Co | MEDICAMENT FOR EXTERNAL APPLICATION CONTAINING AN ANTI-INFLAMMATORY AGENT AND SOYA LECITHIN |
| JP2010043014A (en) * | 2008-08-11 | 2010-02-25 | Japan Algae Kk | Skin cosmetic composition |
| CN104337714A (en) * | 2013-07-29 | 2015-02-11 | 黄庆禄 | Preparation technology of bath fluid containing Chinese herbal medicine polysaccharide |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5473129A (en) * | 1977-11-22 | 1979-06-12 | Asai Germanium Res Inst | External skin remedy |
| JPS5630916A (en) * | 1979-08-23 | 1981-03-28 | Pola Chem Ind Inc | Organogermanium compound, its preparation and external dermatic drug containing the same |
| JPS58140014A (en) * | 1982-02-09 | 1983-08-19 | Ss Pharmaceut Co Ltd | Transparent liquid pharmaceutical composition |
| JPS626A (en) * | 1985-06-25 | 1987-01-06 | Sanae Inazumi | Germanium-containing cosmetic and beauty tool |
| JPS6229521A (en) * | 1985-07-29 | 1987-02-07 | Chubu Seiyaku Kk | Remedy for superficial mycosis |
| JPS63183507A (en) * | 1987-01-22 | 1988-07-28 | Noriyoshi Saeki | Skin cosmetic |
| JPS63313727A (en) * | 1987-06-17 | 1988-12-21 | Noriyoshi Saeki | External remedy |
| JP2002193802A (en) * | 2000-12-28 | 2002-07-10 | Asai Germanium Research Inst | Burn treatment |
-
2003
- 2003-01-31 JP JP2003024614A patent/JP2004231600A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5473129A (en) * | 1977-11-22 | 1979-06-12 | Asai Germanium Res Inst | External skin remedy |
| JPS5630916A (en) * | 1979-08-23 | 1981-03-28 | Pola Chem Ind Inc | Organogermanium compound, its preparation and external dermatic drug containing the same |
| JPS58140014A (en) * | 1982-02-09 | 1983-08-19 | Ss Pharmaceut Co Ltd | Transparent liquid pharmaceutical composition |
| JPS626A (en) * | 1985-06-25 | 1987-01-06 | Sanae Inazumi | Germanium-containing cosmetic and beauty tool |
| JPS6229521A (en) * | 1985-07-29 | 1987-02-07 | Chubu Seiyaku Kk | Remedy for superficial mycosis |
| JPS63183507A (en) * | 1987-01-22 | 1988-07-28 | Noriyoshi Saeki | Skin cosmetic |
| JPS63313727A (en) * | 1987-06-17 | 1988-12-21 | Noriyoshi Saeki | External remedy |
| JP2002193802A (en) * | 2000-12-28 | 2002-07-10 | Asai Germanium Research Inst | Burn treatment |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1852130A4 (en) * | 2005-02-25 | 2008-04-16 | Hisamitsu Pharmaceutical Co | MEDICAMENT FOR EXTERNAL APPLICATION CONTAINING AN ANTI-INFLAMMATORY AGENT AND SOYA LECITHIN |
| JP2010043014A (en) * | 2008-08-11 | 2010-02-25 | Japan Algae Kk | Skin cosmetic composition |
| CN104337714A (en) * | 2013-07-29 | 2015-02-11 | 黄庆禄 | Preparation technology of bath fluid containing Chinese herbal medicine polysaccharide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101659100B1 (en) | Cleansing compositions including modified sorbitan siloxanes and use thereof | |
| DK2744474T3 (en) | MEDICAL SKIN PROTECTION PREPARATION WITH A COMBINATION OF ACTIVE SUBSTANCES THAT IMPROVES THE SKIN BARRIER | |
| ITMI991884A1 (en) | COMPOSITIONS FOR SKIN CARE AND THEIR USE IN CARE FOR DAMAGED SKIN | |
| JPH11158026A (en) | Moisturizing agent and skin lotion | |
| BRPI0817386B1 (en) | "cleaning compositions including modified sorbitan siloxanes and their use" | |
| JP3426436B2 (en) | Skin cosmetics | |
| KR101605324B1 (en) | Cosmetic composition for moisturizing skin which alleviates itchiness and dryness by removing keratin and increasing moisture | |
| JP2004231600A (en) | Skin care preparation for external use | |
| JP2004182639A (en) | Skin care preparation composition for external use | |
| JP2020111581A (en) | Use of alkyloxazolidinone as moisturizing cosmetic agent and method of moisturizing the skin | |
| JPH10279421A (en) | Preparation for external use for skin | |
| JP3532713B2 (en) | Skin cosmetics | |
| JPH03291207A (en) | Dermatic agent for external use | |
| JP2566792B2 (en) | Hair growth and hair growth promoter | |
| JP3534947B2 (en) | External preparation for skin | |
| KR101061612B1 (en) | Cosmetic composition for promoting exfoliation | |
| JP2829157B2 (en) | External preparation for skin | |
| JP4327989B2 (en) | Hair cosmetics | |
| JP2000281558A (en) | Composition for external use | |
| JPH0499707A (en) | Dermal cosmetic | |
| JP3506839B2 (en) | External preparation for skin | |
| JPH0692290B2 (en) | Skin cosmetics | |
| JPS62126106A (en) | Skin cosmetic | |
| JPH10130133A (en) | Skin cosmetic | |
| JPH09188603A (en) | Skin cosmetic material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051104 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090623 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091027 |